Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report

被引：0
作者：
Caroline Y. Chen
Charlene M. Fares
Daniel Sanghoon Shin
机构：
[1] University of California Los Angeles,Department of Medicine, Division of Hematology/Oncology
[2] UCLA Medical Center,Department of Medicine, Division of Hematology/Oncology
[3] University of California Los Angeles,Division of Hematology/Oncology
[4] VA Greater Los Angeles Healthcare System,undefined
来源：
Journal of Medical Case Reports | / 15卷
关键词：
Non-small cell lung cancer; Tyrosine kinase inhibitors; Neoadjuvant; Case report;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 29 条
  • [1] Siegel RL(2019)Cancer statistics, 2019 CA Cancer J Clin 69 7-34
  • [2] Miller KD(2017)Lung cancer: current therapies and new targeted treatments Lancet 389 299-311
  • [3] Jemal A(2013)Treatment of Stage III non-small cell lung cancer Chest 143 e314S-e340S
  • [4] Hirsch FR(2018)Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer J Clin Oncol 36 841-849
  • [5] Scagliotti GV(2019)Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR mutation-positive non-small cell lung cancer: a prospective, single-arm Phase II Study Oncologist 24 157-1929
  • [6] Mulshine JL(2017)Preoperative neoadjuvant gefitinib used in the treatment of a nonsmall cell lung cancer patient Transl Surg 2 22-2245
  • [7] Ramnath N(2017)Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer N Engl J Med 377 1919-e27
  • [8] Dilling TJ(2019)Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study J Clin Oncol 37 2235-104
  • [9] Harris LJ(2019)A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L) Clin Lung Cancer. 20 e25-undefined
  • [10] Ramalingam SS(2019)SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer J Clin Oncol. 37 97-undefined
123